Announcements Trials
Browse Landscape

Phase

Phase 1 69Phase 1/2 32Phase 2 17Phase NA 3Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 38Gynecologic 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 718Lung Neoplasms 310Small Cell Lung Carcinoma 111Neoplasms 42Adenocarcinoma of Lung 40Neoplasm Metastasis 35Parkinson Disease 4, Autosomal Dominant Lewy Body 22Brain Neoplasms 21Carcinoma 19Breast Neoplasms 18Lung Diseases 15NSCLC 14Mesothelioma, Malignant 14Thoracic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Prostatic Neoplasms 11Pleural Effusion, Malignant 10Non-Squamous Non-Small Cell Lung Cancer 10Mesothelioma 10Cachexia 10Respiratory Tract Neoplasms 9Pain 9Bronchial Neoplasms 9Respiratory Tract Diseases 8Carcinoma, Squamous Cell 8Carcinoma, Bronchogenic 8Adenocarcinoma 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × Thoracic × Clear all
NCT03815643 2026-03-31

Avelumab Program Rollover Study

EMD Serono

Phase 3 Active not recruiting
205 enrolled
GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡